GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Sale Of Business

CASI Pharmaceuticals (CASI Pharmaceuticals) Sale Of Business

: $0.00 Mil (TTM As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

CASI Pharmaceuticals's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means CASI Pharmaceuticals gained $0.00 Mil from selling business. CASI Pharmaceuticals's sale of business for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2023 ), CASI Pharmaceuticals gained the same money from selling business in Dec. 2023 ($0.00 Mil).

CASI Pharmaceuticals Sale Of Business Historical Data

The historical data trend for CASI Pharmaceuticals's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CASI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sale Of Business Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CASI Pharmaceuticals Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Sale Of Business Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Sale Of Business
Comparable Companies
DYAI UNCY DARE ICU EFTR CLRB APM TARA EYEN OKYO OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
N/A
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
Website
https://www.casipharmaceuticals.com
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065